Literature DB >> 1844688

One-sided and two-sided tests and p values.

G G Koch1.   

Abstract

Several considerations for the use of one-sided and two-sided tests are discussed: the inferential posture of the design of a study, the level of stringency for supporting a conclusion, the style for reporting p values, the perspective for interpreting results in the opposite direction to the one initially expected, and the role of confidence intervals. The suggestions for addressing these issues for confirmatory biopharmaceutical studies with one-sided objectives are as follows: 1. Clear documentation of the one-sided inferential posture of a study in its protocol. 2. Sufficient sample size for at least moderate power for evaluation with two-sided stringency. 3. Use of one-sided p values to express direction of results together with distinct flags for those which are suitably extreme to support inferences for the target direction or to merit description for the opposite direction. 4. Interpretation of opposite direction results in a post hoc, exploratory, descriptive way rather than inferentially. 5. Provision of one-sided confidence intervals to clarify the nature of one-sided inferences. Alternatively, for academic studies where publication with an inferential posture is of interest for either potential direction of findings, two-sided methods are typically useful. An underlying reason for this is the adjustment provided by two-sided methods for the multiplicity in the two complementary one-sided counterparts that they encompass.

Entities:  

Mesh:

Year:  1991        PMID: 1844688     DOI: 10.1080/10543409108835014

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  1 in total

1.  A letter to the editor in reply to "susceptibility to guillain-barre syndrome is associated to polymorphisms of CD1 genes" by Caporale et al. in the J of Neuroimmunology (2006), 177:112-118.

Authors:  Heejung Bang; Madhu Mazumdar; Dmitri Zaykin
Journal:  J Neuroimmunol       Date:  2007-04-16       Impact factor: 3.478

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.